Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial publishing date : 2021 - 09 - 30 save search
Repare Therapeutics to Present Initial Data from the Phase 1/2 TRESR RP-3500 Clinical Trial at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
Published: 2021-09-30 (Crawled : 00:00) - biospace.com/
RPTX 4 | $3.38 3.68% 3.55% 180K
|
Health Technology
|
| O: 0.89%
H: 4.97%
C: 1.16%
phase 1 molecular cancer trial conference
Olema Oncology Announces Trials in Progress Poster on OP-1250 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Published: 2021-09-30 (Crawled : 23:00) - globenewswire.com
OLMA | $9.98 1.11% 1.1% 580K
|
Health Technology
|
| O: 1.6%
H: 4.57%
C: 3.93%
molecular cancer trials trial conference
AbbVie Presents Late-Breaking Data on Risankizumab (SKYRIZI®) in Psoriatic Arthritis at the 30th European Academy of Dermatology and Venereology (EADV) Congress
Published: 2021-09-30 (Crawled : 19:00) - biospace.com/
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 0.33%
H: 1.12%
C: -1.22%
europe risankizumab
AbbVie Presents New Analyses Evaluating RINVOQ® (upadacitinib) in Atopic Dermatitis Across Patient Characteristics and Body Regions at EADV Virtual Congress
Published: 2021-09-30 (Crawled : 19:00) - biospace.com/
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 0.33%
H: 1.12%
C: -1.22%
dermatitis atopic dermatitis
Scholar Rock Presents Exploratory Responder Analysis on Efficacy Data from the Apitegromab TOPAZ Phase 2 Trial at the Child Neurology Society Annual Meeting
Published: 2021-09-30 (Crawled : 17:00) - biospace.com/
SRRK 4 | $14.79 5.64% 5.34% 740K
|
Health Technology
|
| O: 0.48%
H: 7.02%
C: 4.83%
phase 2 trial
Promising New OpRegen® Clinical Data Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.
Published: 2021-09-30 (Crawled : 17:00) - biospace.com/
LCTX | $1.14 0.0% 330K
|
Health Technology
|
| O: 0.39%
H: 4.71%
C: -1.18%
presentation retina
Tactile Medical Announces Enrollment of First Patient in Randomized, Controlled Clinical Trial Evaluating the Effectiveness of Flexitouch® Plus for the Treatment of Head and Neck Lymphedema
Published: 2021-09-30 (Crawled : 16:00) - globenewswire.com
TCMD | $14.57 -0.55% -0.55% 100K
|
Health Technology
|
| O: 0.86%
H: 1.4%
C: 0.09%
treatment trial enroll
RAPT Therapeutics Announces Late-Breaking Oral Presentation of Positive Results from Phase 1b Trial of RPT193 at the 30th European Academy of Dermatology and Venereology Congress
Published: 2021-09-30 (Crawled : 16:00) - globenewswire.com
RAPT | $8.0 1.78% 1.75% 330K
|
Health Technology
|
| O: 0.71%
H: 3.96%
C: -4.7%
presentation positive results europe phase 1 positive results trial phase 1b phase 2b
Adial Pharmaceuticals Announces Greater Than 50% of Patients Expected to Complete ONWARD™ Phase 3 Trial of AD04 for the Treatment of Alcohol Use Disorder Have Completed the Full 24-Week Treatment Period – Trial Completion Anticipated Q1 2022
Published: 2021-09-30 (Crawled : 14:00) - globenewswire.com
ADIL | News | $1.73 -8.95% -9.83% 440K
|
Health Technology
|
| O: 0.48%
H: 3.57%
C: 2.14%
alcohol use disorder treatment phase 3 trial
InMed Pharmaceuticals Announces Commencement of Phase 2 Clinical Trial Investigating Cannabinol (CBN), a Rare Cannabinoid, in the Treatment of Epidermolysis Bullosa
Published: 2021-09-30 (Crawled : 13:00) - biospace.com/
INM 4 | $0.279 -0.32% -0.32% 89K
|
Health Technology
|
| O: -2.2%
H: 1.84%
C: -1.69%
treatment phase 2 trial cannabinol rare
Plus Therapeutics to Present ReSPECT™-GBM Clinical Trial Data at the 2021 SNO Annual Meeting
Published: 2021-09-30 (Crawled : 12:15) - globenewswire.com
PSTV | News | $1.65 -0.6% -0.61% 17K
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: -0.52%
trial
OpGen Initiates Clinical Trial for Unyvero Urinary Tract Infection Panel
Published: 2021-09-30 (Crawled : 12:00) - globenewswire.com
OPGN | $0.598 -5.18% 50K
|
Commercial Services
|
| O: 0.36%
H: 4.66%
C: 3.23%
trial injection infections
Bausch + Lomb Announces Statistically Significant Topline Results from the Second Phase 3 Trial Of NOV03 (perfluorohexyloctane) in Dry Eye Disease Associated with Meibomian Gland Dysfunction
Published: 2021-09-30 (Crawled : 12:00) - biospace.com/
BHC | $8.53 0.95% 0.0% 4M
|
Health Technology
|
| O: -0.39%
H: 0.61%
C: -0.64%
dry eye disease eye eye disease results topline phase 3 trial
AE Industrial Partners Acquires HealthWay, a Global Leader in Air Purification Technology Solutions
Published: 2021-09-30 (Crawled : 11:00) - prnewswire.com
ACM | $93.88 1.57% 0.0% 470K
|
Industrial Services
|
| O: 0.74%
H: 0.31%
C: -1.9%
technology trial air purifier
Immunic, Inc. Enrolls First Patient in Its Phase 2 CALLIPER Trial of IMU-838 in Progressive Multiple Sclerosis
Published: 2021-09-30 (Crawled : 11:00) - prnewswire.com
IMUX | $1.25 1.63% 1.6% 200K
|
Health Technology
|
| O: 0.33%
H: 0.2%
C: -2.96%
multiple sclerosis phase 2 sclerosis trial dhodh enroll imu-838
Industrial Pump Rental Market Size Worth $ 1.51 Billion | +17,000 Technavio Reports Covering 800 Technologies
Published: 2021-09-30 (Crawled : 08:00) - prnewswire.com
XYL | News | $130.72 1.35% 0.0% 950K
|
Producer Manufacturing
|
| O: 0.36%
H: 0.35%
C: -3.56%
trial
GenFleet and Innovent Starts First-in-human Phase I/II Trial of KRAS G12C Inhibitor
Published: 2021-09-30 (Crawled : 01:00) - prnewswire.com
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 1.05%
H: 1.88%
C: -0.74%
trial
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.